Deals & Corporate Governance

  • April 03, 2026

    Law360 Announces The Members Of Its 2026 Editorial Boards

    Law360 is pleased to announce the formation of its 2026 Editorial Advisory Boards.

  • April 03, 2026

    Aetna Escapes COVID Testing Payment Suit In Calif.

    A Nebraska testing laboratory failed to prove that Aetna underpaid more than $53 million for COVID-19 testing services, a California federal judge has ruled, dismissing the lab's federal racketeering and state law claims against the insurer but leaving the door open to an amended suit. 

  • April 02, 2026

    FTC Warns About Ending Tenn. Oversight Of Ballad Health

    Federal Trade Commission staff has warned Tennessee legislators about the potential harm to patients if they pass a proposal to end the state's oversight of Ballad Health while the hospital system still has a monopoly.

  • April 02, 2026

    Alexion Beats Trade Secret Claims In Amyndas Suit

    Amyndas Pharmaceuticals failed to specifically identify the trade secrets it claimed pharmaceutical company Alexion learned of during early partnership talks and improperly used to launch a business collaboration with another competitor, a Massachusetts federal judge has found.

  • April 02, 2026

    Trump Orders 100% Pharma Tariff, Modifies Metals Duties

    Later this year, the U.S. will impose 100% tariffs on imported pharmaceuticals, but drug companies could qualify for reduced tariff rates as low as zero if they agree to invest domestically and enter most-favored-nation drug-pricing agreements with the government, according to an executive order President Donald Trump signed Thursday.

  • March 31, 2026

    Anesthesia Parent Can't Duck Antitrust Suit, But Affiliate Can

    The parent company of U.S. Anesthesia Partners Inc. remains in the crosshairs of a private antitrust suit accusing it of trying to monopolize Texas anesthesia services, while a federal judge dismissed for now claims against an affiliate that he said was too far removed from the alleged rollup strategy.

  • March 31, 2026

    Biogen Paying $5.6B For Apellis As 4 Firms Advise

    Biogen Inc. said Tuesday that it has agreed to acquire Apellis Pharmaceuticals Inc. in a cash transaction valued at about $5.6 billion, with four law firms steering the transaction focused on key therapies for kidney and eye disorders. 

  • March 25, 2026

    Co.'s Dual Citizenship Doesn't Kill Jurisdiction, 4th Circ. Told

    A medical supply company urged the Fourth Circuit on Wednesday to revive its suit against a U.K. company over COVID-19 test kits, arguing the Chinese citizenship of one of its members doesn't destroy a North Carolina federal judge's ability to hear the case.

  • March 25, 2026

    Covington, Freshfields Advise On $6.7B Merck Oncology Deal

    Merck & Co. said Wednesday it will acquire clinical-stage oncology company Terns Pharmaceuticals Inc. for $53 per share in cash, giving the deal an equity value of $6.7 billion.

  • March 24, 2026

    Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP

    Sarepta Therapeutics Inc. wants the full Federal Circuit to rethink a decision reviving a University of Pennsylvania gene therapy patent, saying a panel got its analysis of patent eligibility wrong.

  • March 24, 2026

    ITC Says Hydrafacial Patent Infringed, But Won't Ban Imports

    The U.S. International Trade Commission has found that an aesthetics medical device company infringed a Hydrafacial LLC skin treatment patent, but stopped short of enforcing a ban on imports.

  • March 24, 2026

    Genesis Gets OK For $7.3M Employee Bonus Plan

    A Texas bankruptcy judge Tuesday gave Genesis Healthcare permission to pay up to $7.3 million in bonuses to executives and other employees, agreeing with the nursing home chain that the workers are needed to keep the business running until its Chapter 11 sale closes.

  • March 24, 2026

    Eldercare Atty On $110M Verdict After Nursing Home Death

    The liability landscape for investors in the long-term care industry shifted with a big-dollar California jury verdict. Law360 talked to plaintiffs counsel Ed Dudensing about the trial and legal accountability of corporate owners.

  • March 23, 2026

    Amarin Tells Justices Hikma Drug Patent Appeal Threatens IP

    Amarin Pharma Inc. has urged the U.S. Supreme Court to uphold a decision that it plausibly alleged that generics maker Hikma Pharmaceuticals USA Inc. encouraged infringement of patents on the heart drug Vascepa, saying a reversal "would dramatically dilute intellectual property protection throughout the nation."

  • March 23, 2026

    Revance Investors Ink $17M Deal In Take-Private Offer Suit

    Dermal fillers company Revance Therapeutics Inc. and two of its executives have agreed to a $17 million settlement to end claims the company hurt investors after the value of a take-private tender offer was negotiated down following allegations that Revance had breached a distribution deal with another company.

  • March 20, 2026

    CytoDyn Settles Investor Suit With $500K, 49M Shares

    Biotechnology firm CytoDyn has agreed to dole out 49 million shares of common stock and pay $500,000 to end investors' proposed class action accusing the company of overstating the likelihood that the U.S. Food and Drug Administration would approve a drug it claimed could treat HIV and COVID-19.

  • March 20, 2026

    Prestige Picks Up Breathe Right In $1.05B Deal

    Consumer healthcare company Prestige Consumer Healthcare Inc. revealed on Friday that it has agreed to acquire a portfolio of brands including Breathe Right nasal strips from Foundation Consumer Healthcare, advised by Skadden Arps Slate Meagher & Flom LLP, in a $1.05 billion deal.

  • March 17, 2026

    NeoGenomics Beats Investor Suit Over Growth Driver Claims

    Cancer diagnostics company NeoGenomics Inc. no longer faces a proposed investor class action alleging it mischaracterized its growth drivers, including by failing to disclose that a rainmaking unit potentially ran afoul of anti-kickback laws, after a Manhattan federal judge held the suit failed to show the company had intentionally misled the markets. 

  • March 17, 2026

    SEIU Pension Fund Wins $842K Suit Against NJ Nursing Home

    A Service Employees International Union pension fund has won its lawsuit accusing a New Jersey nursing home of skipping out on nearly $350,000 in contributions over 13 years, with a D.C. federal judge awarding the fund the missed contributions plus damages after finding it accurately calculated the nursing home's debt.

  • March 17, 2026

    Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033

    Specialty drugmaker Fennec Pharmaceuticals has jointly announced with Indian multinational pharmaceutical company Cipla Ltd. that they had reached an agreement to settle patent infringement litigation in exchange for Cipla delaying the manufacture of a generic pediatric cancer drug until 2033.

  • March 16, 2026

    Italy's Amplifon Buying Danish Hearing Device Biz For $2.6B

    Italy's Amplifon said Monday it has agreed to acquire the hearing device business of Denmark's GN Store Nord in a deal valuing the unit at about €2.3 billion ($2.6 billion), in a move aimed at creating a vertically integrated global leader in audiology.

  • March 16, 2026

    GAO Rejects Unequal Evaluation Claim In CMS Contract

    The U.S. Government Accountability Office found the Centers for Medicare and Medicaid Services did not treat a technology contractor unequally by giving it a low-confidence rating in the technical category even though the winning bidder had time-management issues.

  • March 13, 2026

    Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit

    Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in the complaint was tied to results from a different study that occurred after the IPO.

  • March 12, 2026

    Epilepsy Drugmaker's Statements Insulated From Stock Suit

    A Pennsylvania federal judge has trimmed a shareholder class action against Marinus Pharmaceuticals alleging it misled investors about the probability of success of an epilepsy drug, ruling that certain statements made by company leadership were immunized by the Private Securities Litigation Reform Act.

  • March 11, 2026

    Insulin Makers Ask Justices To Review Collusion Case

    Sanofi-Aventis US, Eli Lilly & Co., Novo Nordisk Inc. and AstraZeneca Pharmaceuticals LP have told the U.S. Supreme Court that a ruling reviving a case over insulin drug costs undermines key rules meant to weed out improper antitrust claims.

Expert Analysis

  • OhioHealth Suit Signals Higher Antitrust Heat On Hospitals

    Author Photo

    The recent antitrust lawsuit against OhioHealth by the U.S. Justice Department and Ohio attorney general shows that federal and state enforcers are closely examining the competition issues in the healthcare sector, including restrictive contracts and antisteering practices, say attorneys at Freshfields.

  • What Changed For Healthcare Transaction Law In 2025

    Author Photo

    Though much of the legislation introduced last year to expand state scrutiny of healthcare transactions did not pass, investors should pay close attention to the overarching trends, which are likely to continue in this year's legislative sessions, say attorneys at Ropes & Gray.

  • Key Trends In Healthcare Antitrust In 2025

    Author Photo

    The healthcare industry braced for significant antitrust enforcement shifts last year driven by a change in administration, and understanding the implications of these trends is critical for healthcare organizations' risk management and strategic decision-making in the year ahead, say attorneys at Michael Best.

  • The 5 Most Important Bid Protest Decisions Of 2025

    Author Photo

    In a shifting bid protest landscape, five decisions in 2025 from the Federal Circuit, the U.S. Court of Federal Claims and the U.S. Government Accountability Office that addressed bedrock questions about jurisdictional reach and the breadth of agency discretion are likely to have a lasting impact, say attorneys at Bradley Arant.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.

  • Nonprofits Face Uncertainty Over Political Activity Rules

    Author Photo

    Two federal court decisions suggesting that the Internal Revenue Service's rules for 501(c)(4) organizations' political activity may be too vague to survive constitutional scrutiny leave nonprofit organizations caught between constitutional limits on government regulation of speech and tax limits on their exempt status, say attorneys at BakerHostetler.

  • Key Takeaways From Armed Services Board's FY 2025 Report

    Author Photo

    The Armed Services Board of Contract Appeals’ annual report reveals an increase in new cases filed, but a decrease in cases resolved, and fewer parties choosing alternative dispute resolution, despite the likely reduction in time and expenses incurred during a prolonged appeal process, say attorneys at Miller & Chevalier.

  • IP Ownership Risk Grows In Booming Cancer Drug Market

    Author Photo

    The ownership of intellectual property has become strategically decisive in deals involving valuable cancer therapeutics known as ADCs, as highlighted by the recent Takeda-Innovent deal, with the commercial value of a license resting on the integrity and defensibility of the underlying technology, say attorneys at Loeb & Loeb.

  • Federal Grantees May Soon Face More Limitations On Speech

    Author Photo

    If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.

  • Considering Judicial Treatment Of The 2023 Merger Guidelines

    Author Photo

    Courts have so far primarily cited the 2023 merger guidelines for propositions that do not differ significantly from prior versions of the guidelines, leaving it unclear whether the antitrust agencies will test the guidelines’ more aggressive theories, and how those theories will be treated by federal judges, say attorneys at Covington.

  • Bid Protest Spotlight: Documentation, Overrides, Eligibility

    Author Photo

    Recent decisions by the U.S. Court of Federal Claims and the U.S. Government Accountability Office illustrate the importance of contemporaneous documentation in proposal evaluations, the standards for an agency’s override of a Competition in Contracting Act stay, and the regulatory requirements for small business joint ventures, says Cody Fisher at MoFo.

  • Calif. Bill May Shake Up Healthcare Investment Landscape

    Author Photo

    If signed by the governor, newly passed California legislation would significantly expand the Office of Health Care Affordability's oversight of private equity and hedge fund investments in healthcare companies and management services organizations, and raise several questions about companies' data confidentiality and filing burdens, say attorneys at Ropes & Gray.

  • FTC Actions Highlight New Noncompete Enforcement Strategy

    Author Photo

    Several recent noncompete-related actions from the Federal Trade Commission — including its recent dismissal of cases appealing the vacatur of a Biden-era noncompete ban — reflect the commission's shift toward case-by-case enforcement, while confirming that the agency intends to remain active in policing such agreements, say attorneys at Debevoise.